ID

17232

Beschrijving

Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00379119

Link

https://clinicaltrials.gov/show/NCT00379119

Trefwoorden

Versies (1)
  1. 01-09-16 01-09-16 -
Geüploaded op

1 september 2016

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Prostate Cancer NCT00379119

Engels

Eligibility Prostate Cancer NCT00379119

1 Formulieren  
Criteria
Beschrijving

Criteria

histologically confirmed adenocarcinoma of the prostate
Beschrijving

adenocarcinoma of the prostate

Datatype

boolean

Alias
UMLS CUI [1]
C0007112
underwent prior radical prostatectomy as local definitive therapy for prostate cancer
Beschrijving

Radical prostatectomy

Datatype

boolean

Alias
UMLS CUI [1]
C0194810
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI-1
C1512693
has received ≥ 9 months of androgen blockade therapy (either single-agent luteinizing hormone-releasing hormone or combined androgen blockade) for serologic progression after surgery
Beschrijving

androgen blockade therapy (either single-agent luteinizing hormone-releasing hormone or combined androgen blockade)

Datatype

boolean

Alias
UMLS CUI [1]
C1518041
UMLS CUI [2]
C3495882
serologic progression defined as a rising prostate-specific antigen, which has risen serially on two determinations (from baseline) ≥ 1 week apart, and no objective evidence of metastatic disease
Beschrijving

rising prostate-specific antigen; no objective evidence of metastatic disease

Datatype

boolean

Alias
UMLS CUI [1]
C0201544
UMLS CUI [2]
C0027627
prior radiotherapy for serologic progression allowed
Beschrijving

Radiotherapy

Datatype

boolean

Alias
UMLS CUI [1]
C1522449
did not receive any form of androgen blockade therapy within the past 9 months
Beschrijving

androgen blockade therapy

Datatype

boolean

Alias
UMLS CUI [1]
C0279492
no metastatic disease by abdominal/pelvic ct scan and whole-body scan
Beschrijving

no metastatic disease by abdominal/pelvic ct scan and whole-body scan

Datatype

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C0203669
UMLS CUI [2,1]
C0027627
UMLS CUI [2,2]
C1641132
Inclusion Criteria: Patient Characteristics
Beschrijving

Inclusion Criteria: Patient Characteristics

Alias
UMLS CUI-1
C0815172
able to tolerate ct scanning in the supine position
Beschrijving

CT scan

Datatype

boolean

Alias
UMLS CUI [1]
C0040405
no prior medical condition known to have effects on the thymus, including myasthenia gravis, lymphoma, hyperthyroidism, or cachexia
Beschrijving

medical condition affecting the thymus, including myasthenia gravis, lymphoma, hyperthyroidism, or cachexia

Datatype

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0040113
UMLS CUI [2]
C0026896
UMLS CUI [3]
C0024299
UMLS CUI [4]
C0020550
UMLS CUI [5]
C0006625
no autoimmune disorders
Beschrijving

autoimmune disorders

Datatype

boolean

Alias
UMLS CUI [1]
C0004364
no acute illness, including active infection requiring antibiotics
Beschrijving

no acute illness, including active infection

Datatype

boolean

Alias
UMLS CUI [1]
C0001314
UMLS CUI [2]
C0009450
prior concurrent therapy: see disease characteristics
Beschrijving

concurrent therapy

Datatype

boolean

Alias
UMLS CUI [1]
C0009429
no prior systemic chemotherapy
Beschrijving

systemic chemotherapy

Datatype

boolean

Alias
UMLS CUI [1]
C1883256
no prior immunological therapy
Beschrijving

immunological therapy

Datatype

boolean

Alias
UMLS CUI [1]
C0021083
no prior single-agent antiandrogen (e.g., high-dose bicalutamide)
Beschrijving

antiandrogen

Datatype

boolean

Alias
UMLS CUI [1]
C0002842
no prior or concurrent 5-alpha reductase inhibitors (e.g., finasteride), pc-spes, or estrogen-containing nutraceuticals
Beschrijving

5-alpha reductase inhibitors, pc-spes, or estrogen-containing nutraceuticals

Datatype

boolean

Alias
UMLS CUI [1]
C2936788
UMLS CUI [2]
C0756934
UMLS CUI [3]
C0014939
no concurrent systemic steroid therapy (topical steroids allowed)
Beschrijving

systemic steroids

Datatype

boolean

Alias
UMLS CUI [1]
C2825233
Terug naar het begin van de pagina

Similar models

Eligibility Prostate Cancer NCT00379119

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
adenocarcinoma of the prostate
Item
histologically confirmed adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
Radical prostatectomy
Item
underwent prior radical prostatectomy as local definitive therapy for prostate cancer
boolean
C0194810 (UMLS CUI [1])
Item Group
Inclusion Criteria
C1512693 (UMLS CUI-1)
androgen blockade therapy (either single-agent luteinizing hormone-releasing hormone or combined androgen blockade)
Item
has received ≥ 9 months of androgen blockade therapy (either single-agent luteinizing hormone-releasing hormone or combined androgen blockade) for serologic progression after surgery
boolean
C1518041 (UMLS CUI [1])
C3495882 (UMLS CUI [2])
rising prostate-specific antigen; no objective evidence of metastatic disease
Item
serologic progression defined as a rising prostate-specific antigen, which has risen serially on two determinations (from baseline) ≥ 1 week apart, and no objective evidence of metastatic disease
boolean
C0201544 (UMLS CUI [1])
C0027627 (UMLS CUI [2])
Radiotherapy
Item
prior radiotherapy for serologic progression allowed
boolean
C1522449 (UMLS CUI [1])
androgen blockade therapy
Item
did not receive any form of androgen blockade therapy within the past 9 months
boolean
C0279492 (UMLS CUI [1])
no metastatic disease by abdominal/pelvic ct scan and whole-body scan
Item
no metastatic disease by abdominal/pelvic ct scan and whole-body scan
boolean
C0027627 (UMLS CUI [1,1])
C0203669 (UMLS CUI [1,2])
C0027627 (UMLS CUI [2,1])
C1641132 (UMLS CUI [2,2])
Item Group
Inclusion Criteria: Patient Characteristics
C0815172 (UMLS CUI-1)
CT scan
Item
able to tolerate ct scanning in the supine position
boolean
C0040405 (UMLS CUI [1])
medical condition affecting the thymus, including myasthenia gravis, lymphoma, hyperthyroidism, or cachexia
Item
no prior medical condition known to have effects on the thymus, including myasthenia gravis, lymphoma, hyperthyroidism, or cachexia
boolean
C0012634 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0040113 (UMLS CUI [1,3])
C0026896 (UMLS CUI [2])
C0024299 (UMLS CUI [3])
C0020550 (UMLS CUI [4])
C0006625 (UMLS CUI [5])
autoimmune disorders
Item
no autoimmune disorders
boolean
C0004364 (UMLS CUI [1])
no acute illness, including active infection
Item
no acute illness, including active infection requiring antibiotics
boolean
C0001314 (UMLS CUI [1])
C0009450 (UMLS CUI [2])
concurrent therapy
Item
prior concurrent therapy: see disease characteristics
boolean
C0009429 (UMLS CUI [1])
systemic chemotherapy
Item
no prior systemic chemotherapy
boolean
C1883256 (UMLS CUI [1])
immunological therapy
Item
no prior immunological therapy
boolean
C0021083 (UMLS CUI [1])
antiandrogen
Item
no prior single-agent antiandrogen (e.g., high-dose bicalutamide)
boolean
C0002842 (UMLS CUI [1])
5-alpha reductase inhibitors, pc-spes, or estrogen-containing nutraceuticals
Item
no prior or concurrent 5-alpha reductase inhibitors (e.g., finasteride), pc-spes, or estrogen-containing nutraceuticals
boolean
C2936788 (UMLS CUI [1])
C0756934 (UMLS CUI [2])
C0014939 (UMLS CUI [3])
systemic steroids
Item
no concurrent systemic steroid therapy (topical steroids allowed)
boolean
C2825233 (UMLS CUI [1])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial